Management of Chronic Lymph Node Enlargement
Initial Evaluation
- A thorough history should include previous lymphoid neoplasms, B-symptoms, and immunosuppression status, as recommended by the American Society of Hematology 1
- Presence of hepatosplenomegaly should be assessed during physical examination, according to the American Society of Hematology 1
Laboratory Investigations
- Complete blood count with differential is recommended for initial evaluation, as suggested by the American Society of Hematology 1
- Blood chemistry including lactate dehydrogenase (LDH) is recommended for initial evaluation, according to the American Society of Hematology 1
- Flow cytometry is recommended for suspected hematologic malignancies, as suggested by the International Society of Hematology 3
Imaging Studies
- CT scan should be considered for persistent lymphadenopathy or when malignancy is suspected, as recommended by the American College of Radiology 2
- PET/CT may be useful for suspected lymphoma with sensitivity of 88% and specificity of 98%, according to the American Urological Association 4
- CT is the imaging method of choice for mediastinal lymphadenopathy, with size criteria (>15 mm short axis) guiding management decisions, as recommended by the American College of Radiology 2
- MRI may be superior for evaluating chest wall involvement and superior sulcus tumors, according to the European Respiratory Society 5
Biopsy Considerations
- Ultrasound-guided FNAC has 93% sensitivity and 91% specificity for palpable nodes, as reported by the American Urological Association 4
- Excisional biopsy should be considered when FNAC is non-diagnostic or lymphoma is suspected, as recommended by the European Hematology Association 6, 7
Disease-Specific Management
- For diffuse large B-cell lymphoma, response assessment should follow standardized criteria evaluating lymph node size regression, as recommended by the European Hematology Association 6, 7, 8
- For chronic lymphocytic leukemia/small lymphocytic lymphoma, CT scans are desirable for evaluation of adenopathy, and response criteria include at least 50% reduction in lymphadenopathy for partial response, as recommended by the National Comprehensive Cancer Network 9